GUIDANCE DOCUMENT
Ethical Considerations for Clinical Investigations of Medical Products Involving Children Draft Guidance for Industry, Sponsors, and IRBs September 2022
Not for implementation. Contains non-binding recommendations.
- Docket Number:
- FDA-2022-D-0738
- Issued by:
-
Guidance Issuing OfficeOffice of the Commissioner, Office of Clinical Policy and Programs, Office of Pediatric TherapeuticsCenter for Biologics Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Drug Evaluation and Research
Clinical investigations in children are essential for obtaining data on the safety and effectiveness of drugs, biological products, and medical devices in children and to protect children from the risks associated with exposure to medical products that may be unsafe or ineffective. Children are a vulnerable population who cannot consent for themselves and who therefore are afforded additional safeguards when participating in a clinical investigation. Such safeguards are an essential requirement for the initiation and conduct of pediatric investigations as part of a medical product development program. This guidance describes the FDA’s current thinking regarding ethical considerations for clinical investigations of medical products in children.
Additional Guidance Resources:
Submit Comments
You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))
If unable to submit comments online, please mail written comments to:
Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document's docket number: FDA-2022-D-0738.